DIVO vs IBB
Amplify CWP Enhanced Dividend Income ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.56% for DIVO.
- • DIVO pays a higher dividend yield (5.07%).
Side-by-side metrics
| Metric | DIVO | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.56% | 0.44% |
Dividend yield Trailing 12-month yield. | 5.07% | 0.23% |
AUM Assets under management — bigger funds are typically more liquid. | $6.97B | $7.95B |
YTD return | 4.40% | 3.10% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.58 | 0.74 |
P/E ratio | 24.34 | 23.72 |
Last price | $45.46 | $170.10 |
Inception | — | — |
Issuer | Amplify | iShares |
DIVO top holdings
| CAT | Caterpillar Inc | 6.20% |
| MSFT | Microsoft Corp | 5.49% |
| AAPL | Apple Inc | 5.08% |
| AXP | American Express Co | 5.07% |
| JPM | JPMorgan Chase & Co | 4.92% |
| GS | The Goldman Sachs Group Inc | 4.88% |
| TJX | TJX Companies Inc | 4.73% |
| RTX | RTX Corp | 4.72% |
| SOFR | Amplify Samsung SOFR ETF | 4.30% |
| V | Visa Inc Class A | 4.28% |
IBB top holdings
| AMGN | Amgen Inc | 7.37% |
| GILD | Gilead Sciences Inc | 7.32% |
| VRTX | Vertex Pharmaceuticals Inc | 7.21% |
| REGN | Regeneron Pharmaceuticals Inc | 6.55% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.71% |
| ARGX | argenx SE ADR | 3.33% |
| INSM | Insmed Inc | 2.70% |
| BIIB | Biogen Inc | 2.67% |
| NTRA | Natera Inc | 2.40% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.27% |
About DIVO
DIVO (Amplify CWP Enhanced Dividend Income ETF) is Quality dividend payers with tactical covered calls. Managed by Amplify, the fund carries $7.0B in assets under management, an expense ratio of 0.56%, a dividend yield of 5.07%. Its largest holding is Caterpillar Inc (CAT), which represents 6.2% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 13.7%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $7.9B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.23%. Its largest holding is Amgen Inc (AMGN), which represents 7.4% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.